Physician profile
Rachel E King
NPI 1780299495
$8,076.67
in general payments reported to CMS, 2019-2025
20 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $1,664 · 2023: $1,459 · 2024: $1,640 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,604.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,628.82 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,410.49 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $701.98 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $591.28 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $514.96 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $468.61 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $418.71 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $354.36 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $349.34 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $307.73 | 2022-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $300.96 | 2022-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $251.79 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $232.02 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $159.13 | 2023-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $129.79 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $72.53 | 2022-2024 | |
| Almatica Pharma LLC | $61.40 | 2022 | |
| Indivior INC. | $59.04 | 2021-2023 | Sublocade, Perseris |
| Biohaven Pharmaceutical Holding Company LTD. | $45.49 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.24 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.